Manufacturing

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Articles

Advances in vaccine development are creating partnerships and stimulating clinical trials to develop new mRNA applications.

Vaccine Development Builds on COVID-19 Breakthroughs

The COVID-19 pandemic has led to many changes and shifts in the pharmaceutical industry, specifically with how pharmaceutical companies develop vaccines.

Recipharm: Combatting Future Viral Threats with Vaccine Advances

Combatting Future Viral Threats with Vaccine Advances

mRNA-1273.222 has also received FDA EUA for children and adolescents between six and 17 years of age and for adults over the age of 18 years of age.

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 

Wai-Chi Man is IC/SP product marketing manager at Thermo Fisher Scientific.

One can improve method precision and productivity by replacing one step in sample preparation with an automated approach.



Automating Glycoprotein Analysis for Vaccine Manufacture

Replacing a step in sample preparation with an automated approach improves both method precision and productivity.

Automating a Critical Step in Glycoprotein Analysis for Vaccine Manufacture

Steriline will be exhibiting its vial filling and capping machine (VFCM100) under double-wall isolator for aseptic filling at CPHI 2022 in Frankfurt, Germany, on Nov. 1–3, 2022.

Steriline Showcases Filling Equipment at CPHI 2022

Julie Vickers is a subject matter expert in Process Engineering at Jacobs.

Peter Cramer is a subject matter expert in Process Architecture at Jacobs.

Ranna Eardley-Patel is a sustainable manufacturing lead at CEPI.

Oliver Excell is an implementation expert at PA Consulting.

This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.

Overcoming Engineering Challenges to Enable Commercial Scale mRNA Vaccine Manufacturing 

Suzanne Shelley is contibuting editor to 

The option of using prefilled syringes for vaccinations is not (yet) available for all types of vaccines. Stakeholders are working to expand that option while also pursuing other non-traditional routes of administration.

Vaccine Administration: The Growing Role of Prefilled Syringes

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

Manufacturing, Vaccines